Arbutus Biopharma Corporation ABUS Interest Expense
Interest Expense at other companies
Other financials
Where this comes from
Reported directly by Arbutus Biopharma Corporation in its filing.
Tagged under the XBRL concept us-gaap:InterestExpenseNonoperating.
The official record: Arbutus Biopharma Corporation’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Arbutus Biopharma Corporation's interest expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Arbutus Biopharma Corporation's interest expense?
- Arbutus Biopharma Corporation (ABUS) reported interest expense of $17K in Q1 2026.
- How has Arbutus Biopharma Corporation's interest expense changed year-over-year?
- Arbutus Biopharma Corporation's interest expense decreased by 39.3% year-over-year, from $28K to $17K.
- What is the long-term trend for Arbutus Biopharma Corporation's interest expense?
- Over 4 years (2021 to 2025), Arbutus Biopharma Corporation's interest expense has grown at a -57.1% compound annual growth rate (CAGR), from $2.86M to $97K.
- What does interest expense mean?
- Cost of borrowing — interest paid or accrued on bonds, bank loans, credit facilities, finance leases, and other debt obligations.